Lapatinib has been evaluated as maintenance therapy in a phase II/III study in patients with EGFR and/or HER2 overexpressing locally advanced or mUC cancer (NCT00949455), but it did not show a clinical benefit of lapatinib compared with placebo [48]. The gene discussed is EGFR; the disease is cancer.